GGrantIndex
← Leaderboards

Jonathan M. Davis

Winthrop-University Hospital

$12,061,854
Attributed
$20,305,808
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY201222
$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$13,612,205 · 4
FDA$6,693,603 · 2

By mechanism

U01$13,145,437 · 2
R01$6,636,398 · 3
R21$523,973 · 1

Top collaborators

Others in their field

Top investigators on “Mothers

Research focus

MothersAffectGenesHigh Risk InfantGeneticLength Of StayInfantPharmaceutical PreparationsIncidencePregnancyGenotypeHospitalsAdultProspectiveHigh RiskDiagnosisNeonateMedicalImproved OutcomeCommon TreatmentNeonatalGenomicsMethadoneCandidate Disease Gene

Grant awards (23)

Precision Medicine in the Diagnosis of Genetic Disorders in Neonates$1,645,739
U01 · FY2022 · TR · contact PI
Advancing standards and methodologies to generate real world evidence from real world data through a neonatal pilot project$1,571,802
U01 · FY2022 · FD
Advancing standards and methodologies to generate real world evidence from real world data through a neonatal pilot project$1,748,239
U01 · FY2021 · FD
Precision Medicine in the Diagnosis of Genetic Disorders in Neonates$1,577,491
U01 · FY2021 · TR · contact PI
Advancing standards and methodologies to generate real world evidence from real world data through a neonatal pilot project$1,777,287
U01 · FY2020 · FD
Precision Medicine in the Diagnosis of Genetic Disorders in Neonates$1,556,802
U01 · FY2020 · TR · contact PI
Precision Medicine in the Diagnosis of Genetic Disorders in Neonates$1,553,519
U01 · FY2019 · TR · contact PI
Precision Medicine in the Diagnosis of Genetic Disorders in Neonates$1,714,558
U01 · FY2018 · TR · contact PI
Establishing Risk in Neonatal Abstinence Syndrome$272,941
R21 · FY2017 · DA · contact PI
Phase 2 Study of rhCC10 to Prevent Neonatal Bronchopulmonary Dysplasia$396,433
R01 · FY2016 · FD · contact PI
Establishing Risk in Neonatal Abstinence Syndrome$251,032
R21 · FY2016 · DA · contact PI
Improving Outcome in Neonatal Abstinence Syndrome$670,027
R01 · FY2015 · DA · contact PI
Phase 2 Study of rhCC10 to Prevent Neonatal Bronchopulmonary Dysplasia$399,983
R01 · FY2015 · FD · contact PI
Improving Outcome in Neonatal Abstinence Syndrome$692,998
R01 · FY2014 · DA · contact PI
Phase 2 Study of rhCC10 to Prevent Neonatal Bronchopulmonary Dysplasia$399,895
R01 · FY2014 · FD · contact PI
Improving Outcome in Neonatal Abstinence Syndrome$671,937
R01 · FY2013 · DA · contact PI
Phase 2 Study of rhCC10 to Prevent Neonatal Bronchopulmonary Dysplasia$399,964
R01 · FY2013 · FD · contact PI
Improving Outcome in Neonatal Abstinence Syndrome$783,536
R01 · FY2012 · DA · contact PI
DELIVERY OF ANTIOXIDANT ENZYMES &GENES TO NEONATAL LUNG$475,074
R01 · FY2004 · HL
DELIVERY OF ANTIOXIDANT ENZYMES &GENES TO NEONATAL LUNG$465,591
R01 · FY2003 · HL
DELIVERY OF ANTIOXIDANT ENZYMES &GENES TO NEONATAL LUNG$455,129
R01 · FY2002 · HL
DELIVERY OF ANTIOXIDANT ENZYMES &GENES TO NEONATAL LUNG$444,970
R01 · FY2001 · HL
DELIVERY OF ANTIOXIDANT ENZYMES &GENES TO NEONATAL LUNG$380,861
R01 · FY2000 · HL